Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Lomustine-temozolomide vs. temozolomide bij glioblastoom met gemethyleerde MGMT-promotor
mrt 2019 | Neuro-oncologie